title: Norchloro-fluoro-homoepibatidine (NCFHEB) - a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET.
abstract: Cholinergic neurotransmission depends on the integrity of nicotinic acetylcholine receptors (nAChRs), and impairment of both is characteristic for various neurodegenerative diseases. Visualization of specific receptor subtypes by positron emission tomography (PET) has potential to assist with diagnosis of such neurodegenerative diseases and with design of suitable therapeutic approaches. The goal of our study was to evaluate in vivo the potential of (18)F-labelled (+)- and (-)-norchloro-fluoro-homoepibatidine ([(18)F]NCFHEB) in comparison to 2-[(18)F]F-A-85380 as PET tracers. In the brains of NMRI mice, highest levels of radioactivity were detected at 20 min post-injection of (+)-[(18)F]NCFHEB, (-)-[(18)F]NCFHEB, and 2-F-[(18)F]-A-85380 (7.45, 5.60, and 3.2% ID/g tissue, respectively). No marked pharmacological adverse effects were observed at 25 mug NCFHEB/kg. Uptake studies in RBE4 cells and in situ perfusion studies suggest an interaction of epibatidine and NCFHEB with the carrier-mediated choline transport at the blood-brain barrier. The data indicate that (+)- and (-)-[(18)F]NCFHEB have potential for further development as PET tracers.
authors.affiliation: Institute of Interdisciplinary Isotope Research, Permoserstrasse 15, 04318 Leipzig, Germany. conrad@iif-leipzig.de
authors.forename: W
authors.initials: W
authors.lastname: Deuther-Conrad
authors.forename: J T
authors.initials: JT
authors.lastname: Patt
authors.forename: P R
authors.initials: PR
authors.lastname: Lockman
authors.forename: D D
authors.initials: DD
authors.lastname: Allen
authors.forename: M
authors.initials: M
authors.lastname: Patt
authors.forename: A
authors.initials: A
authors.lastname: Schildan
authors.forename: V
authors.initials: V
authors.lastname: Ganapathy
authors.forename: J
authors.initials: J
authors.lastname: Steinbach
authors.forename: O
authors.initials: O
authors.lastname: Sabri
authors.forename: P
authors.initials: P
authors.lastname: Brust
mesh_terms: D000818:Animals; D001384:Azetidines; D001549:Benzamides / Q000737:chemistry / Q000493:pharmacokinetics; D001693:Biological Transport, Active; D001812:Blood-Brain Barrier / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry / Q000493:pharmacokinetics; D002794:Choline / Q000378:metabolism; D005260:Female; D007202:Indicators and Reagents; D007553:Isotope Labeling; D008297:Male; D051379:Mice; D010477:Perfusion; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000493:pharmacokinetics; D011978:Receptors, Nicotinic / Q000378:metabolism*; D013237:Stereoisomerism; D014018:Tissue Distribution
chemical_list: C104288:A 85380; D001384:Azetidines; D001549:Benzamides; D019086:Bridged Bicyclo Compounds, Heterocyclic; D007202:Indicators and Reagents; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic; C115362:fluoronorchloroepibatidine; D002794:Choline